Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak

被引:57
作者
Brookmeyer, R [1 ]
Johnson, E
Bollinger, R
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA
[2] Johns Hopkins Sch Med, Div Infect Dis, Baltimore, MD 21205 USA
关键词
D O I
10.1073/pnas.1631983100
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A critical consideration in effective and measured public health responses to an outbreak of inhalational anthrax is the optimum duration of antibiotic prophylaxis. We develop a competing-risks model to address the duration of antibiotic prophylaxis and the incubation period that accounts for the risks of spore germination and spore clearance. The model predicts the incubation period distribution, which is confirmed by empirical data. The optimum duration of antibiotic prophylaxis depends critically on the dose of inhaled spores. At high doses, we show that exposed persons would need to remain on antibiotic prophylaxis for at least 4 months, and considerable morbidity would likely occur before antibiotic prophylaxis could even be initiated. At very low doses, 60 days of antibiotic prophylaxis is adequate. Exposure doses can be estimated from the cumulative attack rate up to the point antibiotic prophylaxis begins. The model explains that whereas :less than or equal to60 days of antibiotics were enough to protect persons in the 2001 U.S. outbreak, because doses were very low, at moderate or high doses considerably longer durations would be necessary to adequately protect exposed populations.
引用
收藏
页码:10129 / 10132
页数:4
相关论文
共 24 条
  • [1] Postexposure prophylaxis against anthrax: Evaluation of various treatment regimens in intranasally infected guinea pigs
    Altboum, Z
    Gozes, Y
    Barnea, A
    Pass, A
    White, M
    Kobiler, D
    [J]. INFECTION AND IMMUNITY, 2002, 70 (11) : 6231 - 6241
  • [2] Brachman P S, 1980, Ann N Y Acad Sci, V353, P83, DOI 10.1111/j.1749-6632.1980.tb18910.x
  • [3] FIELD-EVALUATION OF A HUMAN ANTHRAX VACCINE
    BRACHMAN, PS
    FEKETY, FR
    GOLD, H
    WERRIN, M
    INGRAHAM, NR
    PLOTKIN, SA
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH AND THE NATIONS HEALTH, 1962, 52 (04): : 632 - +
  • [4] INDUSTRIAL INHALATION ANTHRAX
    BRACHMAN, PS
    KAUFMANN, AF
    DALLDORF, FG
    [J]. BACTERIOLOGICAL REVIEWS, 1966, 30 (03) : 646 - &
  • [5] Prevention of inhalational anthrax in the US outbreak
    Brookmeyer, R
    Blades, N
    [J]. SCIENCE, 2002, 295 (5561) : 1861 - 1861
  • [6] Brookmeyer R, 2001, Biostatistics, V2, P233, DOI 10.1093/biostatistics/2.2.233
  • [7] *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P1008
  • [8] Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1024
  • [9] STUDIES ON RESPIRATORY INFECTION .1. THE INFLUENCE OF PARTICLE SIZE ON RESPIRATORY INFECTION WITH ANTHRAX SPORES
    DRUETT, HA
    HENDERSON, DW
    PACKMAN, L
    PEACOCK, S
    [J]. JOURNAL OF HYGIENE, 1953, 51 (03) : 359 - 371
  • [10] POSTEXPOSURE PROPHYLAXIS AGAINST EXPERIMENTAL INHALATION ANTHRAX
    FRIEDLANDER, AM
    WELKOS, SL
    PITT, MLM
    EZZELL, JW
    WORSHAM, PL
    ROSE, KJ
    IVINS, BE
    LOWE, JR
    HOWE, GB
    MIKESELL, P
    LAWRENCE, WB
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (05) : 1239 - 1243